Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial

Fig. 2

28-day survival stratified by baseline IL-18 and treatment simvastatin vs. placebo). Kaplan–Meier curve of survival from enrolment to day 28. Overall p value < 0.001. Patients with high baseline IL-18 (≥ 800 pg/ml) treated with simvastatin vs placebo p = 0.01; patients with low baseline IL-18 (< 800 pg/ml) treated with simvastatin vs. placebo p = 0.75. Interaction of simvastatin and high baseline IL-18 p = 0.19

Back to article page

Critical Care

ISSN: 1364-8535